Clinical Trials Sponsored by Shanghai Zerun Biotechnology Co.,Ltd

Total 1401 results

Shanghai Zerun Biotechnology Co.,Ltd
Yuxi Zerun Biotechnology Co., Ltd.

Completed

Lot Consistency Clinical Trial of Bivalent HPV Vaccine in 9 to 30 Years Old Healthy Females

HPV Infection

China
Shanghai Zerun Biotechnology Co.,Ltd

Completed

Immunogenicity and Safety of Human Papillomavirus (HPV)-16/18 Vaccine in Healthy Females

Human Papillomavirus

China
Shanghai Zerun Biotechnology Co.,Ltd

Active, not recruiting

Evaluation of Safety and Immunogenicity of the Recombinant ZR202-CoV and ZR202a-CoV Vaccines in Adults.

COVID-19 | SARS-CoV-2 Infection

Mali
Shanghai Zerun Biotechnology Co.,Ltd

Completed

A Study of Safety and Primary Immunogenicity of 9-valent HPV Recombinant Vaccine

HPV Infections

China
Shanghai Zerun Biotechnology Co.,Ltd

Unknown

Evaluate the Safety of Recombinant Human Papillomavirus Bivalent (Types 16 and 18) Vaccine (Yeast) in Healthy Females

Human Papillomavirus

China
Shanghai Zerun Biotechnology Co.,Ltd
Walvax Biotechnology Co., Ltd.

Active, not recruiting

Phase II Clinical Trial of Recombinant SARS-CoV-2 Spike Protein Vaccine (CHO Cell) for the Prevention of COVID-19

COVID-19

China
Shanghai Zerun Biotechnology Co.,Ltd
Walvax Biotechnology Co., Ltd.

Active, not recruiting

Safety and Immunogenicity of Recombinant SARS-CoV-2 Spike Protein Vaccine (CHO Cell) for the Prevention of COVID-19

COVID-19

China
Shanghai Zerun Biotechnology Co.,Ltd
Walvax Biotechnology Co., Ltd.

Active, not recruiting

Phase I Clinical Trial of Recombinant SARS-CoV-2 Spike Protein Vaccine (CHO Cell) for the Prevention of COVID-19

COVID-19

China
Shanghai Zerun Biotechnology Co.,Ltd
Walvax Biotechnology Co., Ltd.

Active, not recruiting

Phase III Study Comparing the Immunogenicity of 9-valent HPV Recombinant Vaccine and Gardasil-9

Cervical Cancer | Papillomavirus Infections | CIN | Genital Wart | VIN

China
Shanghai SIMRD Biotechnology Co., Ltd.

Completed

The Pharmacokinetics (PK), Pharmacodynamics(PD), Safety, Tolerability of SR1375 in Healthy Volunteers

Healthy

China
Shanghai SIMRD Biotechnology Co., Ltd.

Completed

The Pharmacokinetics (PK), Safety, Tolerability of SR419 in Healthy Volunteers

Healthy

China
Shanghai Zerun Biotechnology Co.,Ltd
Guangxi Center for Disease Control and Prevention

Completed

Evaluating the 2-dose Immunization Schedule of Human Papillomavirus (HPV)-16/18 in Adolescent Females

Cervical Intraepithelial Neoplasia | Human Papillomavirus | Persistent Infection

China
Shanghai Zerun Biotechnology Co.,Ltd
Guangxi Center for Disease Control and Prevention

Completed

A Phase III Study of Human Papillomavirus (HPV)-16/18 Vaccine.

Cervical Intraepithelial Neoplasia | Human Papilloma Virus Infection Type 16 | Human Papilloma Virus Infection Type 18
Shanghai Escugen Biotechnology Co., Ltd

Not yet recruiting

A Phase III Study of ESG401 for Locally Advanced or Metastatic HR+/HER2- Breast Cancer

Metastatic Breast Cancer

China
Shanghai Kanda Biotechnology Co., Ltd.

Recruiting

KD6001 in Combination With Anti-PD-1 Antibody in Patients With Advanced Melanoma

Melanoma

China
Shanghai Escugen Biotechnology Co., Ltd

Recruiting

Study of ESG401 in Adults With Solid Tumors

Neoplasms, Lung | Neoplasms, Breast | Neoplasms,Colorectal | Neoplasm of Stomach | Neoplasms, Bladder | Neoplasms,Ovarian

China
Shanghai SIMR Biotechnology Co., Ltd.

Completed

To Evaluate the Efficacy and Safety of SR419 in Patients With Postherpetic Neuralgia (PHN)

Postherpetic Neuralgia

China, Australia
Shanghai Gebaide Biotechnology Co., Ltd.

Unknown

A Phase III Trial of Recombinant Human Apo-2 Ligand for Injection

Non-small-cell Lung Cancer (NSCLC) Stage IV

China
Shanghai Synvida Biotechnology Co.,Ltd.

Recruiting

A Clinical Study to Evaluate Safety, Tolerability and Pharmacokinetics of SV001 in Chinese Healthy Adult Volunteers.

Idiopathic Pulmonary Fibrosis

China
Shanghai Kanda Biotechnology Co., Ltd.

Recruiting

A Study of KD6005 in Healthy Participants and Participants With Rheumatoid Arthritis (RA)

Rheumatoid Arthritis

China
Shanghai Kanda Biotechnology Co., Ltd.

Not yet recruiting

KD6001 in Combination With Anti-PD-1 Antibody±Bevacizumab in Patients With Advanced HCC and Other Solid Tumors

Other Solid Tumors | Advanced HCC

China
Shanghai Bovax Biotechnology Co., Ltd.

Recruiting

Immune Persistence After the Whole Vaccination Shcedule With Recombination Quadrivalent HPV Vaccine

Vaginal Cancer | Cervical Cancer Stage IIa | CIN1 | CIN2 | CIN3 | Genital Wart | HPV Infections

China
Shanghai Bovax Biotechnology Co., Ltd.

Completed

Evaluate the Safety and Immunogenicity of a 9-valent HPV Vaccine in Chinese Healthy Male Aged 9-45 Year-old

Anal Cancer | Penile Cancer | Genital Wart | AIN3 | AIN2 | PIN-1 | PIN-2 | PIN-3 | AIN1

China
Shanghai Simnova Biotechnology Co.,Ltd.

Active, not recruiting

Evaluate CART-BCMA in Patients With Relapsed and/or Refractory Multiple Myeloma

Multiple Myeloma

China
Shanghai SIMR Biotechnology Co., Ltd.

Completed

The Pharmacokinetics (PK), Safety, Tolerability of SR750 in Healthy Volunteers

Healthy

China
Shanghai Kanda Biotechnology Co., Ltd.

Completed

Clinical Study of KD6001 in Advanced Solid Tumours

Solid Tumor

China
Shanghai Yizhong Biotechnology Co., Ltd.

Unknown

Paclitaxel Micelles for Injection / Paclitaxel Injection in Combination With Cisplatin for First-line Therapy of Advanced NSCLC

Non-Small Cell Lung Cancer(NSCLC)

China
Shanghai Escugen Biotechnology Co., Ltd

Recruiting

A Phase 1 Study of ESG206 in Adult Subjects With B-cell Lymphoid Malignancies

B-cell Lymphoid Malignancies

China
Shanghai IxCell Biotechnology Co., LTD

Not yet recruiting

Clinical Trial of Human Umbilical Cord Mesenchymal Stem Cells (IxCell hUC-MSC-S) in the Treatment of Ischemic Stroke

Ischemic Stroke
Shanghai Bovax Biotechnology Co., Ltd.

Recruiting

Evaluate the Efficacy, Immunogenicity and Safety of 9-valent HPV Recombinant Vaccine in Chinese Healthy Females

Cervical Cancer | Vulvar Cancer | Vaginal Cancer | CIN1 | CIN2 | CIN3 | VaIN1 | VaIN2 | VaIN3 | Genital Wart | VIN 1 | VIN 2 | VIN 3 | AIS

China
Shanghai Bovax Biotechnology Co., Ltd.

Terminated

A Phase Ⅲ Study to Evaluate the Efficacy, Immunogenicity, Safety of Quadrivalent HPV Recombinant Vaccine in Chinese Healthy Females

Cervical Cancer | CIN1 | CIN2 | CIN3 | Genital Wart | AIS | Vain I | Vain III | Vin I | Vin II | Vin III | VAIN - Vaginal Intraepithelial Neoplasia 2

China
Shanghai Bovax Biotechnology Co., Ltd.

Completed

A Phase I Study of Quadrivalent HPV Recombinant Vaccine

HPV Infections

China
Shanghai iCELL Biotechnology Co., Ltd, Shanghai...

Not yet recruiting

Safety and Efficacy Study of hAESCs Therapy for aGVHD (aGVHD，hAESCs)

GVHD,Acute
Shanghai Ming Ju Biotechnology Co., Ltd.

Recruiting

A Phase 1, Single-arm, Open-label, Dose-escalation Study of JWATM204 as T Cell-targeted Immunotherapy in the Treatment Amongst Subjects With Advanced Hepatocellular Carcinoma

Liver Carcinoma | Hepatic Cell Carcinoma

China
Shanghai Ming Ju Biotechnology Co., Ltd.

Recruiting

Relmacabtagene Autoleucel in Patients With LBCL

Large B-cell Lymphoma

China
CAR-T (Shanghai) Biotechnology Co., Ltd.

Not yet recruiting

Clinical Study on the Safety and Efficacy of Dental Pulp Mesenchymal Cells in the Treatment of Depression

Depression
Shanghai Ming Ju Biotechnology Co., Ltd.

Recruiting

CD19-targeted CAR T Cells for Relapsed and Refractory (R/R) Mantle Cell Lymphoma

Mantle Cell Lymphoma

China
Shanghai Ming Ju Biotechnology Co., Ltd.

Recruiting

CD19-targeted CAR T Cells for Relapsed and Refractory (R/R) Non-Hodgkins Lymphoma

Lymphoma, Non-Hodgkin | Follicular Lymphoma | Diffuse Large B Cell Lymphoma

China
Shanghai Ming Ju Biotechnology Co., Ltd.

Completed

CD19-targeted CAR T Cells （JWCAR029） for Primary Refractory Diffuse Large B Cell Lymphoma

Diffuse Large B Cell Lymphoma

China
CAR-T (Shanghai) Biotechnology Co., Ltd.

Unknown

Novel Coronavirus Induced Severe Pneumonia Treated by Dental Pulp Mesenchymal Stem Cells

COVID-19
CAR-T (Shanghai) Biotechnology Co., Ltd.

Unknown

Clinical Study of Pulp Mesenchymal Stem Cells in the Treatment of Primary Mild to Moderate Knee Osteoarthritis

Knee Osteoarthritis

China
CAR-T (Shanghai) Biotechnology Co., Ltd.

Unknown

Stem Cells From Human Exfoliated Teeth in Treatment of Diabetic Patients With Significantly Reduced Islet Function

Type1diabetes

China
Shanghai Ming Ju Biotechnology Co., Ltd.

Not yet recruiting

Relma-cel for Moderate to Severe Active Systemic Lupus Erythematosus

Systemic Lupus Erythematosus
Shanghai Ming Ju Biotechnology Co., Ltd.

Not yet recruiting

Relmacabtagene Autoleucel as Second-Line Therapy in Adult Patients With Aggressive B-cell NHL

Lymphoma, Large B-Cell, Diffuse | High-grade B-cell Lymphoma | Follicular Lymphoma Grade 3B | Mediastinal B-Cell Diffuse Large Cell Lymphoma

China
Shanghai Ming Ju Biotechnology Co., Ltd.

Recruiting

CD19-CART(Relma-cel) for Moderate to Severe Active Systemic Lupus Erythematosus

Systemic Lupus Erythematosus

China
Shanghai Ming Ju Biotechnology Co., Ltd.

Recruiting

CD19-targeted CAR T Cells for Relapsed and Refractory (R/R) Large B-cell Lymphoma

Lymphoma, Non-Hodgkin | Diffuse Large B Cell Lymphoma

China
Shanghai Ming Ju Biotechnology Co., Ltd.

Not yet recruiting

Relmacabtagene Autoleucel in Hematologic Malignancies

Lymphoma, B-Cell | Follicular Lymphoma | Large B-cell Lymphoma

China
Shanghai Ming Ju Biotechnology Co., Ltd.

Recruiting

CD19-targeted CAR T Cells for Patients With Relapsed or Refractory in B-cell Acute Lymphoblastic Leukemia

Acute Lymphocytic Leukemia

China
CAR-T (Shanghai) Biotechnology Co., Ltd.

Completed

Stem Cells From Human Exfoliated Teeth in Treatment of Type 2 Diabetes

Type2 Diabetes

China
Shanghai Escugen Biotechnology Co., Ltd
Escugen (Australia) Biotechnology Pty Ltd

Not yet recruiting

A First-in-Human Phase I Study of ESG206 in Subjects With B-cell Lymphoid Malignancies

B-cell Lymphoid Malignancies

Clinical Trials Sponsored by Shanghai Zerun Biotechnology Co.,Ltd

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Tanzania

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations